DOCSLIB.ORG

Phase III Trial Results with Blisibimod, a Selective Inhibitor of B-Cell

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Phase III Trial Results with Blisibimod, a Selective Inhibitor of B-Cell UCSF UC San Francisco Previously Published Works Title Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double- blind, placebo-controlled trial. Permalink https://escholarship.org/uc/item/42p3g4xx Journal Annals of the rheumatic diseases, 77(6) ISSN 0003-4967 Authors Merrill, Joan T Shanahan, William R Scheinberg, Morton et al. Publication Date 2018-06-01 DOI 10.1136/annrheumdis-2018-213032 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Downloaded from http://ard.bmj.com/ on April 10, 2018 - Published by group.bmj.com ARD Online First, published on March 21, 2018 as 10.1136/annrheumdis-2018-213032 Clinical and epidemiological research EXTENDED REPORT Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial Joan T Merrill,1 William R Shanahan,2 Morton Scheinberg,3 Kenneth C Kalunian,4 David Wofsy,5 Renee S Martin2 Handling editor Josef S ABSTRacT that the greatest treatment effect is discernible using Smolen Background Targeted inhibitors of B-cell activating more stringent end points and focusing on patients factor (BAFF) have been evaluated in phase III trials in who enter with higher disease activity scores, ► Additional material is published online only. To view, over 4000 patients with systemic lupus erythematosus higher corticosteroid doses, demonstrable antidou- please visit the journal online (SLE). Post hoc analyses of these studies identify greater ble-stranded DNA (dsDNA) and low complement (http:// dx. doi. org/ 10. 1136/ treatment effect in patients entering with higher disease C3 or C4.5 6 annrheumdis- 2018- 213032). activity, greater corticosteroid doses, anti double- These observations provide important guidance 1Oklahoma Medical Research stranded DNA (dsDNA) and low complement C3 or C4. to clinical trial design, especially in light of the Foundation, Oklahoma City, Objectives To evaluate the efficacy and safety of too-common failures of large clinical trials in SLE. Oklahoma, USA blisibimod, a BAFF inhibitor, in a population of patients Moreover, the data provide important guidance to 2 Anthera Pharmaceuticals, Inc, with SLE enriched for high disease activity. treatment practice where use of high-dose cortico- Hayward, California, USA 3 steroids, immunosuppressive agents and cytotoxic Hospital Abreu Sodré (AACD), Methods 442 patients with SLE with antinuclear São Paulo, Brazil antibodies or anti-dsDNA and Safety of Estrogen in agents remain the standard-of-care for moderate 4University of California San Lupus Erythematosus National Assessment – Systemic and severe SLE despite their toxicities.7 8 Diego School of Medicine, La Lupus Erythematosus Disease Activity Index (SELENA- Blisibimod (A-623, AMG 623) is a potent and Jolla, California, USA SLEDAI) score ≥10 on standard-of-care medications selective BAFF inhibitor composed of a tetram- 5University of California, San Francisco, California, USA were randomised to receive weekly subcutaneous eric BAFF binding domain fused to a human IgG1 blisibimod (200 mg) or placebo. Corticosteroid taper was Fc region.9 Although the phase II Placebo-con- Correspondence to encouraged from week 8. The primary end point was the trolled Evaluation of A-623 Response in Lupus Dr Renee S Martin, Anthera week 52 SLE Responder Index-6 (SRI-6). (PEARL-SC) trial with blisibimod in SLE failed to Pharmaceuticals, Inc, Hayward, Results The SRI-6 primary end point was not met. meet the primary efficacy end point, SLE Responder California 94545, USA; There was a statistically significant steroid-sparing Index-5 (SRI-5), it corroborated the observations rmartin@ anthera. com effect, and significantly more blisibimod-treated subjects from larger Phase III trials in that better treat- Received 16 January 2018 achieved corticosteroid taper. Increased blisibimod ment effect was observed in subjects with higher Revised 1 March 2018 treatment effect on SRI-6 was observed in subjects disease activity, taking corticosteroids, who had Accepted 2 March 2018 who achieved a concomitant decrease in corticosteroid abnormalities in anti-dsDNA and/or complement.10 dose from baseline. In subjects with baseline urinary Furthermore, in keeping with the belimumab protein:creatinine ratio (UPCR) ≥56.5 mg/mmol, observations,11 favourable effects on proteinuria significantly higher proportions of blisibimod subjects were observed.10 In addition, blisibimod treatment achieved >50% reduction in UPCR and/or UPCR was associated with significant decreases in anti- <56.5 mg/mmol. Reductions in SLE autoantibodies and dsDNA, immunoglobulins, total B-cell counts and B cells, and increases in complement C3 and C4 were fatigue12 and significant increases in complement observed with blisibimod. Blisibimod was well-tolerated. C3 and C4. Accordingly, the phase III Clinical and The most common adverse events were upper respiratory Health Assessments with BLISibimod SC, Study tract infection, urinary tract infection, injection site 1 (CHABLIS-SC1) trial prospectively evaluated a erythema/reaction and diarrhoea. population of subjects with SLE enriched for the Conclusions Although the SRI-6 end point was traits that, in earlier studies, were associated with not met, blisibimod was associated with successful greater treatment effect relative to background steroid reduction, decreased proteinuria and biomarker standard-of-care treatments. responses. Trial registration number NCT01395745. METHODS Patient population and trial design The CHABLIS-SC1 study (NCT01395745) was To cite: Merrill JT, INTRODUCTION conducted in Belarus, Brazil, Colombia, Georgia, Shanahan WR, Targeted, biologic inhibitors of B-cell activating Guatemala, Hong Kong, Korea, Singapore, Scheinberg M, et al. Ann Rheum Dis Epub ahead factor (BAFF), belimumab and tabalumab, have Malaysia, Mexico, Russia, Sri Lanka, Taiwan, of print: [please include Day been evaluated in four large phase III clinical trials Thailand and the Philippines. The study enrolled Month Year]. doi:10.1136/ in nearly 4000 patients with systemic lupus erythe- 442 adults aged ≥18 years who were seroposi- annrheumdis-2018-213032 matosus (SLE).1–4 Data from these studies indicate tive for anti-nuclear antibody (ANA) (≥1:80 in Merrill JT, et al. Ann Rheum Dis 2018;0:1–7. doi:10.1136/annrheumdis-2018-213032 1 Copyright Article author (or their employer) 2018. Produced by BMJ Publishing Group Ltd (& EULAR) under licence. Downloaded from http://ard.bmj.com/ on April 10, 2018 - Published by group.bmj.com Clinical and epidemiological research Table 1 Demographics and baseline disease characteristics Blisibimod Placebo Overall (n=245) (n=197) (n=442) Age, mean (SD) (years) 36.7 (10.98) 35.6 (10.78) 36.2 (10.89) Gender (female:male, %) 92.7:7.3 94.9:5.1 93.7:6.3 Race, n (%) Black or African-American 10 (4.1) 4 (2.0) 14 (3.2) White 167 (68.2) 132 (67.3) 299 (67.8) Asian 67 (27.3) 60 (30.6) 127 (28.8) Native Hawaiian or other Pacific 1 (0.4) 0 1 (0.2) Islander Figure 1 Disposition of subjects in the CHABLIS-SC1 trial, including Region, n (%) randomisation (5:4) into the treatment arms, numbers of subjects who Asia Pacific 67 (27.3) 60 (30.5) 127 (28.7) completed study and reasons for discontinuation (and numbers of Central and South America 89 (36.3) 58 (29.4) 147 (33.3) subjects). Europe 89 (36.3) 79 (40.1) 168 (38.0) Weight, mean (SD) (kg) 65.1 (15.46) 64.8 (15.31) 65.0 (15.38) BMI, mean (SD) (kg/m2) 25.1 (5.33) 25.0 (4.96) 25.0 (5.17) immunofluorescence assay) or anti-dsDNA (≥30 IU/mL), met SELENA-SLEDAI mean score (SD) 13.4 (4.31) 13.5 (4.01) 13.5 (4.18) at least four of the SLE Classification Criteria defined by the SELENA-SLEDAI activity, n (%) American College of Rheumatology (ACR),13 and had a base- Total score ≤12 133 (54.3) 107 (54.3) 240 (54.3) line disease activity score of ≥10 on the SELENA-SLEDAI scale Total score >12 112 (45.7) 89 (45.2) 201 (45.5) despite concomitant and stable use of systemic corticosteroids at Dermal 234 (95.5) 188 (95.9) 422 (95.7) the lesser of 0.5 mg/kg or 40 mg/day of prednisone or equivalent. Immunologic 222 (90.6) 178 (90.8) 400 (90.7) Other standard-of-care medications in stable doses were allowed Musculoskeletal 193 (78.8) 159 (81.1) 352 (79.8) (antimalarials, methotrexate, mycophenalate, azathioprine, Renal 78 (31.8) 54 (27.6) 132 (29.9) leflunomide, non-steroidal anti-inflammatory drugs). Subjects BILAG A, B or C domain score, n (%) were excluded from study if they had active vasculitis, central Mucocutaneous 236 (96.3) 190 (96.9) 426 (96.6) nervous system lupus or severe active lupus nephritis, protein- Musculoskeletal 209 (85.3) 169 (86.2) 378 (85.7) uria >6 g/24 hours (or equivalent) or a history of malignancy Haematological 121 (49.4) 101 (51.5) 222 (50.3) in the last 5 years, HIV infection, hepatitis B or C infection or Renal 96 (39.2) 64 (32.7) 160 (36.3) tuberculosis or recent use of a B-cell targeted drug, investiga- Constitutional 35 (14.3) 28 (14.3) 63 (14.3) tional agents, cyclophosphamide or other alkylators, transfusion, intravenous immunoglobulin, plasmapheresis, plasma exchange, PGA score, mean (SD) 1.59 (0.475) 1.64 (0.475) 1.61 (0.475) high-dose corticosteroid, antitumour necrosis factor-α or other PGA score (range) 0.1–2.7 0.4–2.8 0.1–2.8 biologics, ciclosporin or live vaccines. Corticosteroid dose (prednisone 15.6 (8.58) 15.6 (9.75) 15.6 (9.11) dose equivalent, mg (SD)) Eligible subjects were randomly assigned using an interac- tive web-based randomisation system in a 5:4 ratio to receive <Median prednisone dose, n (%) 108 (44.1) 103 (52.3) 211 (47.7) subcutaneous blisibimod 200 mg once weekly or corresponding ≥Median prednisone dose, n (%) 137 (55.9) 94 (47.7) 231 (52.3) volume and frequency-matched placebo using a double-blind Systemic SLE medications, n (%) interactive web response system.
Load more

Recommended publications
  • BAFF-Neutralizing Interaction of Belimumab Related to Its Therapeutic Efficacy for Treating Systemic Lupus Erythematosus
    ARTICLE DOI: 10.1038/s41467-018-03620-2 OPEN BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus Woori Shin1, Hyun Tae Lee1, Heejin Lim1, Sang Hyung Lee1, Ji Young Son1, Jee Un Lee1, Ki-Young Yoo1, Seong Eon Ryu2, Jaejun Rhie1, Ju Yeon Lee1 & Yong-Seok Heo1 1234567890():,; BAFF, a member of the TNF superfamily, has been recognized as a good target for auto- immune diseases. Belimumab, an anti-BAFF monoclonal antibody, was approved by the FDA for use in treating systemic lupus erythematosus. However, the molecular basis of BAFF neutralization by belimumab remains unclear. Here our crystal structure of the BAFF–belimumab Fab complex shows the precise epitope and the BAFF-neutralizing mechanism of belimumab, and demonstrates that the therapeutic activity of belimumab involves not only antagonizing the BAFF–receptor interaction, but also disrupting the for- mation of the more active BAFF 60-mer to favor the induction of the less active BAFF trimer through interaction with the flap region of BAFF. In addition, the belimumab HCDR3 loop mimics the DxL(V/L) motif of BAFF receptors, thereby binding to BAFF in a similar manner as endogenous BAFF receptors. Our data thus provides insights for the design of new drugs targeting BAFF for the treatment of autoimmune diseases. 1 Department of Chemistry, Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 05029, Republic of Korea. 2 Department of Bio Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Republic of Korea. These authors contributed equally: Woori Shin, Hyun Tae Lee, Heejin Lim, Sang Hyung Lee.
    [Show full text]
  • Study Protocol
    PROTOCOL SYNOPSIS A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus International Coordinating Investigator Study site(s) and number of subjects planned Approximately 450 subjects are planned at approximately 173 sites. Study period Phase of development Estimated date of first subject enrolled Q2 2015 3 Estimated date of last subject completed Q2 2018 Study design This is a Phase 3, multicentre, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab (150 mg or 300 mg) versus placebo in subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE) while receiving standard of care (SOC) treatment. The study will be performed in adult subjects aged 18 to 70 years of age. Approximately 450 subjects receiving SOC treatment will be randomised in a 1:2:2 ratio to receive a fixed intravenous dose of 150 mg anifrolumab, 300 mg anifrolumab, or placebo every 4 weeks (Q4W) for a total of 13 doses (Week 0 to Week 48), with the primary endpoint evaluated at the Week 52 visit. Investigational product will be administered as an intravenous (IV) infusion via an infusion pump over a minimum of 30 minutes, Q4W. Subjects must be taking either 1 or any combination of the following: oral corticosteroids (OCS), antimalarial, and/or immunosuppressants. Randomisation will be stratified using the following factors: SLE Disease Activity Index 2000 (SLEDAI-2K) score at screening (<10 points versus ≥10 points); Week 0 (Day 1) OCS dose 2(125) Revised Clinical Study Protocol Drug Substance Anifrolumab (MEDI-546) Study Code D3461C00005 Edition Number 5 Date 18 May 2016 (<10 mg/day versus ≥10 mg/day prednisone or equivalent); and results of a type 1 interferon (IFN) test (high versus low).
    [Show full text]
  • Rheumatology and CTD
    Section 16 Section Editor: G Narsimulu Rheumatology and CTD 206. Refractory Rheumatoid Arthritis 214. Treatment of SLE beyond Steroids Rohini Handa Rathindra Nath Sarkar, Rudrajit Paul 207. Difficulties in Rheumatoid Arthritis 215. Gout Is the Only Enemy That I Do Not Rajan Kumar Wish to Have at My Feet Anjana Pandey, Ajay Maurya, PK Maheshwari 208. Monoarthritis—A Clinical Dilemma to Internists Arup Kumar Kundu, Abhishek Kundu 216. Liver Dysfunction and NAFLD in RA: 209. Oral Targeted Treatments in RA—Update 2021 Is MTX Really a Culprit? Ramakrishna Rao Uppuluri, Sripurna Deepti Challa Kartik Nikhil Balankhe, Rishabh Ramu Nayak, Pulin Kumar Gupta 210. Biosimilars: Bane or Boon for India 217. Sexual Dysfunction in Rheumatic Diseases Durga Prasanna Misra, Pallavi Patro, Vikas Agarwal Vinod Ravindran 211. An Approach to Vasculitis 218. Interpretation of Common Investigations Packiamary Jerome in Rheumatology 212. How to Manage DMARDs Failure in RA? Renu Saigal, Amit Kansal, Vikram Raj Jain N Subramanian 213. IgG4-related Disease Harpreet Singh, Somdatta Giri, Anju Arya MU-206 (Sec-16).indd 1321 29-01-2021 15:25:29 MU-206 (Sec-16).indd 1322 29-01-2021 15:25:30 CHAPTER 206 Refractory Rheumatoid Arthritis Rohini Handa Abstract A sizeable number of patients with rheumatoid arthritis (RA) are unable to attain low disease activity or remission despite treatment. These difficult to treat (D2T) patients are labeled as refractory RA. The troika of D2T RA, as outlined by the European League against Rheumatism, comprises of treatment failure history, presence of active/symptomatic disease, and clinical perception. The approach to refractory RA is evolving.
    [Show full text]
  • Antagonist Antibodies Against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound S
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2016/07/19/jpet.116.236075.DC1 1521-0103/359/1/37–44$25.00 http://dx.doi.org/10.1124/jpet.116.236075 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 359:37–44, October 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Unexpected Potency Differences between B-Cell–Activating Factor (BAFF) Antagonist Antibodies against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound s Amy M. Nicoletti, Cynthia Hess Kenny, Ashraf M. Khalil, Qi Pan, Kerry L. M. Ralph, Julie Ritchie, Sathyadevi Venkataramani, David H. Presky, Scott M. DeWire, and Scott R. Brodeur Immune Modulation and Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut Received June 20, 2016; accepted July 18, 2016 Downloaded from ABSTRACT Therapeutic agents antagonizing B-cell–activating factor/B- human B-cell proliferation assay and in nuclear factor kB reporter lymphocyte stimulator (BAFF/BLyS) are currently in clinical assay systems in Chinese hamster ovary cells expressing BAFF development for autoimmune diseases; belimumab is the first receptors and transmembrane activator and calcium-modulator Food and Drug Administration–approved drug in more than and cyclophilin ligand interactor (TACI). In contrast to the mouse jpet.aspetjournals.org 50 years for the treatment of lupus. As a member of the tumor system, we find that BAFF trimer activates the human TACI necrosis factor superfamily, BAFF promotes B-cell survival and receptor. Further, we profiled the activities of two clinically ad- homeostasis and is overexpressed in patients with systemic vanced BAFF antagonist antibodies, belimumab and tabalumab.
    [Show full text]
  • 1 the BAFF/APRIL System in SLE Pathogenesis. Fabien B Vincent1
    . Fabien B Vincent1, Eric F Morand2, Pascal Schneider3 and Fabienne Mackay1 1 Department of Immunology, Monash University, Central Clinical School, Alfred Medical Research and Education Precinct (AMREP), 89 Commercial Road, Melbourne, Victoria 3004, Australia 2 Monash University Centre for Inflammatory Diseases, Southern Clinical School, Monash Medical Centre, 246 Clayton Road, Clayton, Victoria, 3168, Australia 3 Department of Biochemistry, University of Lausanne, Boveresses 155, 1066 Epalinges, Switzerland Abstract Systemic lupus erythematosus (SLE) is characterized by multisystem immune-mediated injury in the setting of autoimmunity to nuclear antigens. The clinical heterogeneity of SLE, the absence of universally agreed clinical trial end points, and the paucity of validated therapeutic targets have, historically, contributed to a lack of novel treatments for SLE. However, in 2011, a therapeutic monoclonal antibody that neutralizes the cytokine TNF ligand superfamily member 13B (also known as B-cell-activating factor of the TNF family [BAFF]), belimumab, became the first targeted therapy for SLE to have efficacy in a randomized clinical trial. Because of its specificity, the efficacy of belimumab provides an opportunity to increase understanding of SLE pathophysiology. Although belimumab depletes B cells, this effect is not as powerful as that of other B-cell-directed therapies that have not been proven efficacious in randomized clinical trials. In this article, therefore, we review results suggesting that neutralizing BAFF can have effects on the immune system other than depletion of B cells. We also identify aspects of the BAFF system for which data in relation to SLE are still missing, and we suggest studies to investigate the pathogenesis of SLE and ways to refine anti-BAFF therapies.
    [Show full text]
  • The Future of B-Cell Activating Factor Antagonists in the Treatment of Systemic Lupus Erythematosus
    pISSN: 2093-940X, eISSN: 2233-4718 Journal of Rheumatic Diseases Vol. 24, No. 2, April, 2017 https://doi.org/10.4078/jrd.2017.24.2.65 Review Article The Future of B-cell Activating Factor Antagonists in the Treatment of Systemic Lupus Erythematosus William Stohl Division of Rheumatology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA To review B-cell activating factor (BAFF)-antagonist therapy in systemic lupus erythematosus (SLE), literature was searched us- ing the search words and phrases, “BAFF”, “B lymphocyte stimulator (BLyS)”, “a proliferation-inducing ligand (APRIL)”, “B-cell maturation antigen (BCMA)”, “transmembrane activator and calcium-modulating and cyclophilin ligand interactor (TACI)”, “BLyS receptor 3 (BR3)”, “belimumab”, “atacicept”, “blisibimod”, “tabalumab”, and “lupus clinical trial”. In addition, papers from the author’s personal library were searched. BAFF-antagonist therapy in SLE has a checkered past, with four late-stage clin- ical trials meeting their primary endpoints and four failing to do so. Additional late-stage clinical trials are enrolling subjects to address some of the remaining unresolved questions, and novel approaches are proposed to improve results. The BAFF-centric pathway is a proven therapeutic target in SLE. As the only pathway in the past 50+ years to have yielded an United States Food and Drug Administration-approved drug for SLE, it occupies a unique place in the armamentarium of the practicing rheumatologist. The challenges facing clinicians and investigators are how to better tweak the BAFF-centric pathway and im- prove on the successes realized. (J Rheum Dis 2017;24:65-73) Key Words.
    [Show full text]
  • Therapeutics Advisory Group
    Therapeutics Advisory Group CCG and NHS Trusts in Norfolk and Waveney Index of TAG recommendations Generic name Indication BNFclass Trafficlight IQoro euromuscular training Hiatus hernia - improving symptoms No BNF entry - device Double Red Not recommended for device routine use / Not commissioned (L-) Carnitine Carnitine Deficiency 9.8.1 Drugs used in Red Hospital / Specialist metabolic disorders only (Para-)aminosalicylic acid Tuberculosis 5.1.9 Antituberculosis Double Red Not recommended for drugs - routine use / Not Antimycobacterials commissioned 5-fluorouracil + salicyclic acid Hyperkeratotic actinic keratosis 13.8.1 Photodamage Double-GreenSuitable for GPs to topical solution initiate and prescribe 5-fluorouracil 5% w/w cream Non-hypertrophic actinic keratosis 13.8.1 Photodamage Double-GreenSuitable for GPs to initiate and prescribe Abacavir HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist antiretroviral drugs only Abacavir + dolutegravir + HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist lamivudine antiretroviral drugs only Abacavir and lamivudine HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist antiretroviral drugs only Abaloparatide Male and juvenile osteoporosis 6.6.1 Calcitonin and Double Red Not recommended for Calcitonin and routine use / Not parathyroid hormone commissioned Abatacept Rheumatoid arthritis - 1st line biologic 10.1.3 Drugs that suppress Red Hospital / Specialist after failure of non-biologic DMARDs
    [Show full text]
  • Immunfarmakológia Immunfarmakológia
    Gergely: Immunfarmakológia Immunfarmakológia Prof Gergely Péter Az immunpatológiai betegségek döntő többsége gyulladásos, és ennek következtében általában szövetpusztulással járó betegség, melyben – jelenleg – a terápia alapvetően a gyulladás csökkentésére és/vagy megszűntetésére irányul. Vannak kizárólag gyulladásgátló gyógyszereink és vannak olyanok, amelyek az immunreakció(k) bénításával (=immunszuppresszió révén) vagy emellett vezetnek a gyulladás mérsékléséhez. Mind szerkezetileg, mind hatástanilag igen sokféle csoportba oszthatók, az alábbi felosztás elsősorban didaktikus célokat szolgál. 1. Nem-szteroid gyulladásgátlók (‘nonsteroidal antiinflammatory drugs’ NSAID) 2. Kortikoszteroidok 3. Allergia-elleni szerek (antiallergikumok) 4. Sejtoszlás-gátlók (citosztatikumok) 5. Nem citosztatikus hatású immunszuppresszív szerek 6. Egyéb gyulladásgátlók és immunmoduláns szerek 7. Biológiai terápia 1. Nem-szteroid gyulladásgátlók (NSAID) Ezeket a vegyületeket, melyek őse a szalicilsav (jelenleg, mint acetilszalicilsav ‘aszpirin’ használatos), igen kiterjedten alkalmazzák a reumatológiában, az onkológiában és az orvostudomány szinte minden ágában, ahol fájdalom- és lázcsillapításra van szükség. Egyes felmérések szerint a betegek egy ötöde szed valamilyen NSAID készítményt. Szerkezetük alapján a készítményeket több csoportba sorolhatjuk: szalicilátok (pl. acetilszalicilsav) pyrazolidinek (pl. fenilbutazon) ecetsav származékok (pl. indometacin) fenoxiecetsav származékok (pl. diclofenac, aceclofenac)) oxicamok (pl. piroxicam, meloxicam) propionsav
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0216742 A1 Demartino Et Al
    US 2013 0216742A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0216742 A1 DeMartino et al. (43) Pub. Date: Aug. 22, 2013 (54) DELAMINATION RESISTANT Related U.S. Application Data PHARMACEUTICAL, GLASS CONTAINERS (60) Provisional application No. 61/551,163, filed on Oct. CONTAINING ACTIVE PHARMACEUTICAL 25, 2011, provisional application No. 61/656,998, INGREDIENTS filed on Jun. 7, 2012. (71) Applicants: Steven Edward DeMartino, Painted Publication Classification Post, NY (US); John Stephen Peanasky, Big Flats, NY (US); Robert (51) Int. Cl. Anthony Schaut, Painted Post, NY A61. I/00 (2006.01) (US); Wendell P. Weeks, Corning, NY CO3C 4/20 (2006.01) (US) (52) U.S. Cl. (72) Inventors: Steven Edward DeMartino, Painted CPC. A61J I/00 (2013.01); C03C4/20 (2013.01) Post, NY (US); John Stephen USPC ......................................................... 428/34.4 Peanasky, Big Flats, NY (US); Robert (57) ABSTRACT Anthony Schaut, Painted Post, NY The present invention is based, at least in part, on the identi (US); Wendell P. Weeks, Corning, NY fication of a pharmaceutical container formed, at least in part, (US) of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particu (21) Appl. No.: 13/660,680 lates. As a result, the presently claimed containers are par ticularly Suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a (22) Filed: Oct. 25, 2012 pharmaceutically active ingredient. Patent Application Publication Aug. 22, 2013 Sheet 1 of 9 US 2013/0216742 A1 Fis, 8, 2 Patent Application Publication Aug. 22, 2013 Sheet 2 of 9 US 2013/0216742 A1 ***, F & 3 - -i Patent Application Publication Aug.
    [Show full text]
  • Supplementary Material Table of Contents
    Supplementary M aterial Table of Contents 1 - Online S u pplementary Methods ………………………………………………...… . …2 1.1 Study population……………………………………………………………..2 1.2 Quality control and principal component analysis …………………………..2 1.3 Statistical analyses………………………………………… ………………...3 1.3.1 Disease - specific association testing ……………………………… ..3 1.3.2 Cross - phenotype meta - analysis …………………………………… .3 1.3.3 Model search ……………………………………………………… .4 1.3.4 Novelty of the variants …………………………………………… ..4 1.3.5 Functional Enrichment Analy sis ………………………………… ...4 1.3.6 Drug Target Enrichment Analysis ………………………………… 5 2 - Supplementary Figures………………………………………...………………… . …. 7 3 - Members of the Myositis Genetics Consortium (MYOGEN) ……………………. ..16 4 - Members of the Scleroderma Genetics Consortium ………………… ……………...17 5 - Supplementary References………………………………………………………… . .18 6 - Supplementary Tables………………………………………………………… . ……22 1 Online supplementary m ethods Study population This study was conducted using 12,132 affected subjects and 23 ,260 controls of European des cent population and all of them have been included in previously published GWAS as summarized in Table S1. [1 - 6] Briefly, a total of 3,255 SLE cases and 9,562 ancestry matched controls were included from six countrie s across Europe and North America (Spain, Germany, Netherlands, Italy, UK, and USA). All of the included patients were diagnosed based on the standard American College of Rheumatology (ACR) classification criteria. [7] Previously described GWAS data from 2,363 SSc cases and 5,181 ancestry
    [Show full text]
  • NIH Public Access Author Manuscript Curr Allergy Asthma Rep
    NIH Public Access Author Manuscript Curr Allergy Asthma Rep. Author manuscript; available in PMC 2013 December 01. Published in final edited form as: Curr Allergy Asthma Rep. 2012 December ; 12(6): 495–510. doi:10.1007/s11882-012-0307-y. Cellular Targeting in Autoimmunity Jennifer L. Rogers, Donald S. Serafin, Roman G. Timoshchenko, and Teresa K. Tarrant $watermark-textUniversity $watermark-text of North $watermark-text Carolina School of Medicine Division of Rheumatology, Allergy, and Immunology and the Thurston Arthritis Research Center CB#7280, 3300 Manning Dr. Chapel Hill, NC 27517 Abstract Many biologic agents that were first approved for the treatment of malignancies are now being actively investigated and used in a variety of autoimmune diseases such as rheumatoid arthritis (RA), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, systemic lupus erythematosus (SLE), and Sjogren’s syndrome. The relatively recent advance of selective immune targeting has significantly changed the management of autoimmune disorders, and in part, can be attributed to the progress made in understanding effector cell function and their signaling pathways. In this review, we will discuss the recent FDA approved biologic therapies that directly target immune cells as well as the most promising investigational drugs affecting immune cell function and signaling for the treatment of autoimmune disease. Keywords Autoimmune disease; Autoimmunity; Biologic therapy; Rheumatoid arthritis; Systemic lupus erythematosus; ANCA associated vasculitis; Sjogren’s syndrome; B cell; T cell; Tyrosine kinase inhibitors; chemokine receptors; Cellular targeting INTRODUCTION There have been important advances in our understanding of the pathogenesis of autoimmune disease over the past two decades, which have led to an expanding array of biologic therapeutics targeting selective immune responses.
    [Show full text]
  • Novel Therapeutic Agents in Clinical Development for Systemic Lupus Erythematosus Natasha Jordan, Pamela MK Lutalo and David P D’Cruz*
    Jordan et al. BMC Medicine 2013, 11:120 http://www.biomedcentral.com/1741-7015/11/120 Cutting edge: issues in autoimmunity REVIEW Open Access Novel therapeutic agents in clinical development for systemic lupus erythematosus Natasha Jordan, Pamela MK Lutalo and David P D’Cruz* Abstract Conventional immunosuppressive therapies have radically transformed patient survival in systemic lupus erythematosus (SLE), but their use is associated with considerable toxicity and a substantial proportion of patients remain refractory to treatment. A more comprehensive understanding of the complexity of SLE immunopathogenesis has evolved over the past decade and has led to the testing of several biologic agents in clinical trials. There is a clear need for new therapeutic agents that overcome these issues, and biologic agents offer exciting prospects as future SLE therapies. An array of promising new therapies are currently emerging or are under development including B-cell depletion therapies, agents targeting B-cell survival factors, blockade of T-cell co-stimulation and anti-cytokine therapies, such as monoclonal antibodies against interleukin-6 and interferon-α. Keywords: Lupus nephritis, B-cell depletion, BLys, T-cell co-stimulation, Interferon-α, SLE Introduction of Afro-Caribbean descent [6]. A significant proportion of Systemic lupus erythematosus (SLE) is a complex auto- lupus nephritis patients are refractory to conventional im- immune rheumatic disease, characterized by unpredict- munosuppressive agents and the potential side effects of able exacerbations and remissions. Clinical manifestations these therapies remain significant. are variable ranging from arthralgia, photosensitivity and A retrospective review of lupus nephritis patients over a the classic ‘butterfly’ rash to internal organ involvement, 30-year period (1975 to 2005) from a single center showed most notably renal and central nervous system disease [1].
    [Show full text]